[PRESSWIRE] Dublin, IRELAND - 14.03.23 -- Global Software Company Cubic Telecom has today announced three new senior leadership appointments that support the company’s long-term growth projections and strategic priorities.  With the appointments of a new Chief Technology Officer, Chief Product Officer and Chief Corporate Officer, the Senior Leadership Team now stands at eight, which signifies the growing success of the company over the past number of years.   

[PRESSWIRE] Calgary, Alberta, Canada – March 14, 2023 -- Volt Carbon Technologies Inc. (“Volt Carbon” or the “Company”) (TSX-V: VCT) (OTCQB: TORVF) in conjunction with Downsview Aerospace Innovation & Research (DAIR) is pleased to announce that its subsidiary, Solid Ultrabattery Inc. is a successful applicant of the DAIR Green Fund for a project titled “Development of lithium-ion battery for small drone and UAV applications.”

[PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Massachusetts – March 13, 2023 – ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that new preclinical data for ProMIS’ lead candidate for AD, PMN310, will be presented as a virtual short oral poster presentation at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2023) to be held on March 28-April 1, 2023 virtually and in Gothenburg, Sweden.

[PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Massachusetts – March 13, 2023 – ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced an oral presentation and two onsite poster presentations at the upcoming American Academy of Neurology (AAN) Annual Meeting, which will be held on April 22-27, 2023 in Boston, MA. The presentations highlight ProMIS’ broad pipeline of next-generation neurodegenerative disease therapeutics, including data that further characterize lead drug AD candidate, PMN310, as well as preclinical optimization studies of an Alzheimer’s vaccine and data supporting RACK1 as a potential target in amyotrophic lateral sclerosis (ALS).

[PRESSWIRE] Vancouver, British Columbia – March 13, 2023 – Dear Shareholders, it has been a fast paced start to 2023 for NevGold Corp. (“NevGold” or the “Company”) (TSXV:NAU) (OTCQX:NAUFF) (Frankfurt:5E50), with a lot of positive operational progress since closing our oversubscribed +C$4.1M financing on December 5, 2022. I write this update to shareholders very excited about what the future has in store as we drill our first holes at Nutmeg Mountain in Idaho, and continue our resource development and exploration at Limousine Butte in Nevada. The NevGold story has significantly advanced and evolved since our first day of public trading on June 29, 2021 and we are dedicated to becoming one of the “go-to” oxide, heap-leach gold resource development and exploration companies in the Western USA.

[PRESSWIRE] Denmark – 09.03.23 -- DigiShares, a global provider of infrastructure for tokenization of real-world assets, has recently introduced three new configurations of its market leading platform, to cater for three different market segments. This enables DigiShares to support the main three tokenization use cases, crypto-settled, fiat-settled, and internally settled. Each configuration is optimized for full automation and ease of use.

[PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Massachusetts – March 8, 2023 – ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced its full year 2022 financial results and recent highlights.

[PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Massachusetts – March 8, 2023 – ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that Gail Farfel, Ph.D., Chief Executive Officer, will present at the upcoming Oppenheimer 33rd Annual Conference on Monday, March 13, 2023 at 12:30 p.m. ET.

[PRESSWIRE] London, UK - 06.03.23 -- UK financial services firms such as banks are spending around £194.6million per year protecting themselves and their customers against fraud and financial crime.

[PRESSWIRE] Denmark – 02.03.23 -- DigiShares is kicking off its Series A capital raise today. The raise is taking the form of a Security Token Offering (STO). The tokens will be minted on the Ethereum chain. Investors will be able to purchase ERC-1404 security tokens representing ownership in DigiShares’ Delaware Corporation.